Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to US$665 million including potential development milestones and its second acquisition announced this month.
Astellas ramps up M&A, buys US biotech Xyphos for as much as US$665 million
